NCT06284668

Esketamine vs Remimazolam for Postoperative Sleep Disturbance and Anxiety

Esketamine vs Remimazolam for Postoperative Sleep Disturbance and Anxiety in Patients Undergoing Oocyte Retrieval

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 315 (actual)
• Sponsor: Tianjin Medical University General Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

To explore and compare the effects of esketamine and remimazolam on postoperative sleep disturbance in patients undergoing oocyte retrieval

Detailed description

Postoperative sleep disturbance (PSD) occur in the form of sleep deprivation, circadian rhythm disturbance, and structural abnormalities, and have a high incidence in patients undergoing surgery. Postoperative sleep disorders can lead to postoperative delirium and cognitive dysfunction, aggravate postoperative acute pain, and delay postoperative recovery. Benzodiazepines have a certain sedative hypnotic anti-anxiety effect, and remimazolam as a new benzodiazepine, its sedative hypnotic anti-anxiety effect is worthy of further exploration. Esketamine is an N-methyl-D-aspartate(NMDA) receptor antagonist with analgesic and sedative effects, and is widely used in clinical treatment of refractory depression. For patients undergoing surgery, in addition to sedation and analgesia, whether the intraoperative use of esketamine has positive effects on postoperative sleep disturbance is worth exploring.

Conditions

• Sleep Disturbance

Interventions

Type	Name	Description
DRUG	normal Saline	Patients undergoing oocyte retrieval were given 5ml 0.9% saline before anesthesia and surgery
DRUG	Esketamine	Patients undergoing oocyte retrieval were given esketamine 0.2mg/kg before anesthesia and surgery
DRUG	Remimazolam	Patients undergoing oocyte retrieval were given remimazolam 0.2mg/kg before anesthesia and surgery

Timeline

• Start date: 2024-03-04
• Primary completion: 2025-05-10
• Completion: 2025-05-20
• First posted: 2024-02-29
• Last updated: 2025-11-26

Locations

1 site across 1 country: China